目的 建立超高效液相色谱串联质谱法,同时测定缬沙坦胶囊和分散片中N-亚硝基二甲胺(NDMA)和N-亚硝基二乙胺(NDEA)2个亚硝胺类遗传毒性杂质的残留量。方法 采用安捷伦Zorbax Eclipse Plus C18色谱柱(3.0 mm×150 mm,1.8 μm),以0.1%甲酸水溶液为流动相A,甲醇为流动相B,进行梯度洗脱,流速为0.5 mL·min-1。质谱采用大气压化学电离(APCI)离子源,多反应监测(MRM)正离子检测模式进行定量分析。结果 NDMA和NDEA线性范围、灵敏度、精密度、准确度、专属性均满足分析要求。经检验,102批缬沙坦胶囊和52批缬沙坦分散片中,NDMA和NDEA含量均不超过定量限浓度,均符合规定。结论 本方法操作简便、快速、准确、灵敏度高、专属性好,适用于缬沙坦胶囊和分散片中NDMA和NDEA的限度检查和定量检测。
Abstract
OBJECTIVE To establish a method for simultaneous determination of two nitrosamine genotoxic impurities, N-nitrosodimethylamine(NMDA) and N-nitrosodiethylamine(NDEA), in valsartan formulations using ultra-high performance liquid chromatography triple quadrupole mass spectrometry(UHPLC-MS/MS). METHODS The separation was performed on an Agilent Zorbax Eclipse Plus C18 column(3.0 mm×150 mm, 1.8 μm) with mobile phase consisting of 0.1% formic acid aqueous solution(A) and methanol(B) by gradient elution at a flow rate of 0.5 mL·min-1, and the column oven temperature was maintained at 40 ℃. Multiple reaction monitoring(MRM) was conducted in positive ion mode using atmospheric pressure chemical ionization(APCI) interface. The optimal voltages, currents, and gas flows were chosen to provide the best sensitivity and specificity for each MRM ion pair. Mass transitions m/z 75.0→58.1 and m/z 75.0→43.0 were set as quantitative and qualitative ion pairs for NDMA, and mass transitions m/z 103.0→75.0 and m/z 103.0→47.0 were set as quantitative and qualitative ion pairs for NDEA. RESULTS The calibration curves had good linearity within the ranges of 0.3-50 ng·mL-1 and 0.06-10 ng·mL-1 for NDMA and NDEA, respectively. The limits of quantitation(LOQ) of NDMA and NDEA were 0.03 μg·g-1 and 0.006 μg·g-1, respectively. The recovery of NDMA was within the range of 92.3%-111.7%(RSD<5.0%), and the recovery of NDEA was between 90.6% and 106.0%(RSD<5.0%). The specificity and precision of the method were also validated. One hundred and two batches of valsartan capsules and 52 batches of valsartan dispersible tablets were analyzed by this method, and the amounts of NDMA and NDEA were all no more than the LOQ values. Therefore, all the samples met the limit requirement. CONCLUSION The established method is simple, rapid, accurate, sensitive and specific for limit test and quantitative analysis of NDMA and NDEA in valsartan formulations.
关键词
超高效液相色谱串联质谱法 /
缬沙坦 /
遗传毒性杂质 /
N-亚硝基二甲胺 /
N-亚硝基二乙胺
{{custom_keyword}} /
Key words
UHPLC-MS/MS /
valsartan /
genotoxic impurity /
N-nitrosodimethylamine /
N-nitrosodiethylamine
{{custom_keyword}} /
中图分类号：
R917
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] FDA. Information about nitrosamine impurities in medications [EB/OL].(2021-11-18) [2021-12-17]. https://www.fda.gov/drugs/drug-safety-and-availability/information-about-nitrosamine-impurities-medications.
[2] BEARD J C, SWAGER T M. An organic chemist′s guide to N-nitrosamines: Their structure, reactivity, and role as contaminants [J]. J Org Chem, 2021, 86(3): 2037-2057.
[3] ZHENG J L, DANIEL C R, HATIA R I, et al. Dietary N-nitroso compounds and risk of hepatocellular carcinoma: A USA-based study [J]. Hepatology, 2021, 74(6): 3161-3173.
[4] SHEWEITA S A, ELBANNA Y Y, BALBAA M, et al. N-nitrosamines induced infertility and hepatotoxicity in male rabbits [J]. Environ Toxicol, 2017, 32(9): 2212-2220.
[5] DIETRICH M, BLOCK G, POGODA J M, et al. A review: dietary and endogenously formed N-nitroso compounds and risk of childhood brain tumors [J]. Cancer Causes Control, 2005, 16(6): 619-635.
[6] ICH. M7(R1) Assessment and control of DNA reactive(mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk [EB/OL].(2017-03-31) [2021-12-17]. https://database.ich.org/sites/default/files/M7_R1_Guideline.pdf.
[7] Center for drug evaluation. Guideline for research techniques of nitrosamine impurities in chemical drugs(Trial) [EB/OL].(2020-05-08) [2021-12-17]. https://www.cde.org.cn/main/news/viewInfoCommon/776b663787ec5a60ac7440 71c3714d5a.
[8] CPDB. All results on each chemical in the carcinogenic potency database(CPDB) [EB/OL].(2007-10-03) [2021-12-17]. https://files.toxplanet.com/cpdb/chemnameindex.html.
[9] FDA. Control of nitrosamine impurities in human drugs: Guidance for industry [EB/OL].(2021-02-24) [2021-12-17]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/control-nitrosamine-impurities-human-drugs.
[10] HOU J F, LI M, KOU J P, et al. Determination of four nitrosamine genotoxic impurities in valsartan by UPLC-MS/MS method [J]. Chin Pharm J(中国药学杂志), 2021, 56(10): 842-848.
[11] YUAN S, HUANG H W, YU Y J, et al. Determination of seven N-nitrosamines genotoxic impurities in losartan potassium and valsartan by UPLC-MS/MS [J]. Chin J Pharm Anal(药物分析杂志), 2021, 41(7): 1218-1225.
[12] XU Y M, HAN B, YAN K, et al. Simultaneous detection of 3 N-nitrosamine genotoxic impurities in irbesartan [J]. Chin J Pharm Anal(药物分析杂志), 2021, 41(4): 720-725.
[13] ZOU Y, SUN L P, LI X D, et al. Determination of N-nitroso-N-methyl-4-aminobutyric acid in losartan potassium using high performance liquid chromatography triple quadrupole mass spectrometry [J]. Chin Pharm J(中国药学杂志), 2020, 55(3): 228-232.
[14] LIU J, XIE B, MAI B, et al. Development of a sensitive and stable GC-MS/MS method for simultaneous determination of four N-nitrosamine genotoxic impurities in sartan substances [J]. J Anal Sci Technol, 2021, 12(3): 1-8.
[15] GE Y Q, YE X X, LE J, et al. Simultaneous determination of genotoxic N-nitrosamine impurities in irbesartan preparations by GC-MS/MS [J]. Chin J Pharm(中国医药工业杂志), 2020, 51(6): 759-764.
[16] LI J, CHEN H B, WANG Y Y, et al. Microdetermination of N-nitrosodimethylamine and N-nitrosodiethylamine in candesartan cilexetil by GC-MS [J]. Chin J Mod Appl Pharm(中国现代应用药学), 2020, 37(13): 1615-1620.
[17] JIANG J, ZOU Y, SUN L P, et al. Determination of N-nitrosodimethylamine and N-nitrosodiethylamine in irbesartan using headspace gas chromatography mass spectrometry [J]. Chin J Anal Lab(分析试验室), 2020, 39(2): 245-248.
[18] SCHMIDTSDORFF S, SCHMIDT A H. Simultaneous detection of nitrosamines and other sartan-related impurities in active pharmaceutical ingredients by supercritical fluid chromatography [J]. J Pharm Biomed Anal, 2019, 174: 151-160.
[19] USP. General chapter <1469> nitrosamine impurities [EB/OL].(2021-12-01) [2021-12-17]. https://online.uspnf.com/uspnf/document/1_GUID-C97F817C-A383-4693-8E0C-2F0A0A371977_2_en-US.
[20] EDQM. 2.5.42 N-nitrosamines in active substances [EB/OL].(2020-12-07) [2021-12-17]. https://www.edqm.eu/sites/default/files/medias/fichiers/European_Pharmacopoeia/News/european_pharmacopoeia_n-nitrosamines_in_active_substances.pdf.
[21] Chinese Pharmacopoeia Commission. Publication of the second revised draft of national standard of valsartan [EB/OL].(2019-01-02) [2021-12-17]. https://www.chp.org.cn/gjyjw/hxyp/5182.jhtml.
[22] EDQM. New OMCL method for simultaneous determination of NDMA and NDEA in sartans [EB/OL].(2018-10-11) [2021-12-17]. https://www.edqm.eu/en/news/new-omcl-method-simultaneous-determination-ndma-and-ndea-sartans.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(2241 KB)
